38th Annual J.P. Morgan Healthcare Conference

January 13, 2020

2

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this presentation include, among others, statements regarding our preliminary estimates of fourth quarter and fiscal year 2019 revenue, and our expectations for commercial launches, availability of study data and submission of regulatory filings. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in actions or decisions by the FDA, the EMA or other regulatory authorities regarding whether to accept or approve drug applications that may be filed, including delays or denials of regulatory approvals,clearances or authorizations for applications, as well as their decisions regarding drug labeling, reimbursement and pricing. Furthermore, we are in the process of finalizing our financial results for the fourth quarter and fiscal year 2019, and therefore our finalized and audited results and final analysis of those results are not yet available. The preliminary expectations regarding 2019 revenue are subject to management’s review and actual results could differ from management’s expectations. The actual results are also subject to audit by our independent registered public accounting firm and no assurance is given by our independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December 31, 2019 based on the foregoing estimates. These forward-looking statements speak only as of thedate hereof. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.

Forward-looking Statements

3

Introduction• Estimated $38.3-39.3M in Rubraca® (rucaparib) global ovarian sales for Q4 2019 and $142.0-143.0M for

FY2019

• EU ovarian launches underway in Germany, England and Italy; additional EU ovarian launches anticipated in Q1 2020

• sNDA for Rubraca in BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer filed in mid-November 2019

• Potential U.S. prostate cancer launch in mid-2020

• Multiple studies underway of combinations of Bristol-Myers Squibb’s Opdivo® (nivolumab) with both Rubraca and lucitanib

• Initial data from lucitanib combination studies anticipated at medical meetings in 2020

• Recently acquired rights to FAP-2286, a radiopharmaceutical therapy targeting FAP; Clovis currently planning to file IND in 2H 2020

– Encouraging initial clinical experience reported based on named-patient use

– Potential to be a leader in an emerging area of oncology development

• Reduced outstanding convertible debt by $123.4M in early January 2020 sNDA = Supplemental New Drug Application

4

U.S. Commercial Team Actively Promoting Recurrent Ovarian Maintenance Indication and Preparing for Prostate Launch

• Rubraca is indicated to treat women with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status

• Indication based on data from the Phase 3 ARIEL3 clinical trial

• Approximately 140 field-based personnel in U.S.promoting Rubraca and educating HCPs

• Organization in place to support potential prostate cancer launch in mid-2020

Source: Rubraca [prescribing information]. Boulder, CO; Clovis Oncology.

5

Rubraca Launch Underway in the EU for Recurrent Ovarian Cancer Maintenance Treatment Indication• In January 2019, the European

Commission approved the use of Rubraca for its second indication

– With the maintenance treatment indication, Rubraca is available to eligible patients regardless of their BRCA mutation status

• Launches underway in Germany, England and Italy; launches in Spain and France planned for Q1 2020

LaunchedLaunch Q1 2020

6

Rubraca Potential in Prostate Cancer

• Second most frequently diagnosed cancer in men

– An estimated 175,000 men in the U.S. diagnosed in 2019

– Approximately 450,000 men in Europe diagnosed in 2018

• Castration-resistant prostate cancer (CRPC) has high likelihood of developing metastases

– Approximately 43,000 men in the U.S. expected to be diagnosed with mCRPC in 2020

– The 5-year survival rate is ~30% for metastatic disease

– mCRPC remains an incurable disease usually associated with poor prognosis

• Approximately ~12% of mCRPC patients have a deleterious mutation in BRCA1 or BRCA2

– These molecular markers may be used to select patients for treatment with a PARP inhibitor

Sources: American Cancer Society accessed 12/2019; WHO GLOBOCAN accessed 12/2019; Scher HI et al (2015) Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 10(10): e0139440. doi:10.1371/journal.pone.0139440; Robinson et al. Cell. 2015; 161:1215-1228; Abida et al. JCO Precis Oncol. 2017;1:1-16; Green et al. AACR 2019 Poster Presentation

7

Potential Launch in Prostate Cancer in mid-2020

• Clovis submitted the sNDA for BRCA1/2-mutant recurrent, metastatic castrate-resistant

prostate cancer in mid-November 2019

– ESMO 2019 data from TRITON2 included 57 patients with BRCA1/2-mutant tumors and

measurable disease

– sNDA based on the TRITON2 data presented at ESMO 2019, as well as additional patients,

and additional data maturity on the patients reported at ESMO 2019

– sNDA data set consistent with data reported at ESMO

8

TRITON2: Study in mCRPC

TRITON2: A Phase 2 single-arm study Initiated Q4 2016

• Enrolling patients with germline or somatic BRCA mutations as well as other deleterious mutations in other HR repair genes

• All patients received one previous line of taxane-based chemo and one or two lines of AR-targeted therapy in the castrate-resistant setting

• Primary endpoints are confirmed radiologic ORR per modified RECIST/PCWG3 in patients with measurable disease by independent review and PSA response rate in patients without measurable disease

TRITON2 clinicaltrials.gov identifier NCT02952534HR = homologous recombination, AR = androgen receptor, ORR = overall response rate, PSA = prostate-specific antigen

9

TRITON2 Interim Results Presented at ESMO 2019

• The safety profile of rucaparib was consistent with prior reports from TRITON2 and those in patients with ovarian cancer and other solid tumors

Source: Abida et al. Ann Oncol. 2019; 30:abst 846PD

BRCA1/2 with measurable disease(n=57)

Investigator-Assessed(n=57)

IRR-Assessed(n=57)

ORR, n (%) [95% CI]a 25/57 (43.9)[30.7–57.6]

23/57 (40.4)[27.6–54.2]

Complete response, n (%) 3/57 (5.3) 4/57 (7.0)Partial response, n (%) 22/57 (38.6) 19/57 (33.3)

Stable disease, n (%) 26/57 (45.6) 28/57 (49.1)Progressive disease, n (%) 5/57 (8.8) 5/57 (8.8)Not evaluable, n (%) 1/57 (1.8) 1/57 (1.8)

Overall BRCA1/2(n=98)

Confirmed PSA response rate, n/N (%) [95% CI]51/98 (52.0)[41.7-62.2]

Visit cutoff date: 02 July 2019.aPer modified RECIST/PWCG3 criteria. CI, confidence interval; IRR, independent radiology review; ORR, objective response rate; PCWG3, Prostate Cancer Clinical Trials Working Group 3; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1.

10

TRITON2 Interim Results Presented at ESMO 2019

Enrolment cut-off date: 28 Feb 2019; Visit cut-off date: 02 Jul 2019U, unknownSource: Abida et al. Ann Oncol. 2019; 30:abst 846PD

• Best change from baseline in sum of target lesions in TRITON2 patients with a BRCA1/2 mutation treated with rucaparib (n=56)

11

TRITON3 in Prostate Cancer: Comparative Study for Potential Full Approval

TRITON3: A Phase 3 comparative study Initiated Q1 2017• Enrolling patients with germline or somatic BRCA and ATM mutations whose tumors have progressed

on AR-targeted therapy and who have not yet received chemo in the castrate-resistant setting

• The study will compare rucaparib to physician’s choice of AR-targeted therapy or chemotherapy in these patients

• Primary endpoint is radiologic PFS

• Study could potentially serve as confirmatory should TRITON2 study data support an accelerated approval

TRITON3 clinicaltrials.gov identifier NCT02975934

12

LODESTAR Study to Evaluate Rucaparib in HRR Genes Across Tumor Types

LODESTAR: Phase 2 Tumor-agnostic Basket Study

Initiated Q4 2019

• Evaluating rucaparib as monotherapy treatment in patients with recurrent solid tumors associated with a deleterious HRR gene mutation− Primary Cohort: BRCA1, BRCA2, PALB2, RAD51C, RAD51D− Exploratory Cohort: BRIP1, BARD1, FANCA, NBN, RAD51, RAD51B

• Primary endpoint = Investigator-assessed ORR by RECIST v1.1

• Potentially registration-enabling for targeted gene- and tumor-agnostic label

• Potential sNDA filing in 2021

HRR = homologous recombination repair

LODESTAR clinicaltrials.gov identifier NCT04171700

13

Clinical Collaboration in Place to Explore Rubraca+Opdivo Combinations• Clinical collaboration to evaluate Rubraca in combination with Bristol-Myers Squibb’s anti-

PD-1 Opdivo in multiple tumor types

• Three trials underway or planned:

– Clovis-sponsored ATHENA Trial: Phase 3 in advanced ovarian cancer

– BMS-sponsored CheckMate 9KD Trial: Phase 2 in mCRPC

– BMS-sponsored FRACTION-GC Trial: Phase 2 in advanced gastric cancer

• Clovis retains all rights to Rubraca

14

ATHENA Evaluates Rubraca Monotherapy and Rubraca+Opdivo in Front-Line Ovarian Cancer

ATHENA: Phase 3 comparative study Initiated Q2 2018• A four-arm, first-line maintenance treatment study to evaluate Rubraca and Opdivo, Rubraca, Opdivo and placebo in

newly diagnosed patients with stage III/IV high-grade ovarian cancer

− Switch maintenance design; patient enrolls when surgery/chemotherapy completed

• Objective is to determine if combination of PARP and PD-1 inhibitor meaningfully extends PFS versus Rubraca as monotherapy, or versus placebo

• All-comers population, similar step down statistical plan as ARIEL3

• Anticipate completing enrollment in this 1,000 patient study by mid-year 2020

• Currently expect results from Rubraca monotherapy versus placebo in all study populations in 2H 2021; results expected from Rubraca+Opdivo versus Rubraca in all study populations approximately one year later or more

• Entered into non-dilutive clinical trial financing up to $175M to fund quarterly expenses related to the ATHENA trial

ATHENA clinicaltrials.gov identifier NCT03522246

15

Lucitanib is an Oral Tyrosine Kinase Inhibitor

• Lucitanib is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3), platelet derived growth factor receptors (PDGFR) α/β and fibroblast growth factor receptors 1-3 (FGFR1-3)

Kinase Kd (nM)

FGFR1 21

FGFR2 41

FGFR3 51

VEGFR1 1

VEGFR2 1.1

VEGFR3 7.1

PDGFRα 0.43

PDGFRβ 0.26

Kinome profilingKinase binding profiling

Sources: Clovis internal data; KINOMEscan kinase profiling of 456 kinases with 100 nM lucitanib performed at DiscoveRx; Clovis internal data; Kinase binding performed at DiscoveRx.

16

Lucitanib Overview• Strong rationale to study lucitanib in combinations with checkpoint inhibitors

– Recent data for lenvatinib which inhibits the same three pathways as lucitanib – when combined with the PD-1 inhibitor, pembrolizumab – showed encouraging results

– Preclinical data for lucitanib in combination with PD-1 inhibitor demonstrated enhanced anti-tumor activity compared to that of single agents

• Lucitanib added to Clovis’ clinical collaboration with Bristol-Myers Squibb; combination study with Opdivo in advanced gynecologic cancers, lung cancer and other solid tumors now enrolling

• Based on encouraging preclinical and clinical data of VEGF and PARP inhibitors in combination, a study of lucitanib in combination with Rubraca in advanced ovarian cancer now enrolling

• Clovis owns global rights (excluding China) to lucitanib

17

Lucitanib Clinical Development Plan: Combinations with Opdivo and Rucaparib in Multiple Solid Tumors• Two Clovis-sponsored early Phase 1b/2 lucitanib combinations studies now enrolling

– LIO-1: Lucitanib and anti-PD-1 Opdivo (Bristol-Myers Squibb) combination in advanced gynecologic cancers and other solid tumors

– Lucitanib and rucaparib combination in advanced solid tumors as an arm of the SEASTAR study

• Anticipate initial data at medical meetings in 2020

• BMS-sponsored Phase 1/2 study to initiate in early 2020 to evaluate multiple combinations with Opdivo, including an arm in combination with lucitanib in patients with second-line non-small cell lung cancer

LIO-1 clinicaltrials.gov identifier NCT04042116SEASTAR clinicaltrials.gov identifier NCT03992131CA209-79X clinicaltrials.gov identifier NCT04151563

18

FAP-2286 and Peptide-Targeted Radiopharmaceutical Therapy Program• In September 2019, Clovis Oncology acquired rights to FAP-2286, a radiopharmaceutical

targeting FAP from 3B Pharmaceuticals (3BP)

– Includes U.S. and global rights, excluding Europe (inclusive of Russia, Turkey and Israel), where 3BP retains rights

• Clovis planning to file IND for FAP-2286 in 2H 2020

• FAP highly expressed in multiple tumor types; Clovis to pursue broad and accelerated clinical development program

– FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas

• Clovis acquiring global rights to discovery program for three additional targets for radiopharmaceutical therapy

Source: Rettig et al., 1993; Cancer ResearchFAP = fibroblast activation protein alpha, IND = investigational new drug

19

Introduction to Targeted Radiopharmaceutical Therapy• Targeted radiopharmaceutical therapy involves a small amount

of radioactive material linked to a cell targeting agent for the treatment of cancer

• The targeting agent is able to recognize and bind to specific features of tumors

• When injected into the patient’s bloodstream, the agent attaches to cancer cells, delivering a high dose of radiation to the tumor while sparing normal tissues

• Examples of this therapeutic approach include:

– LUTATHERA® a radiolabeled somatostatin analog approved for the treatment of midgut carcinoid tumors

– 177Lu-PSMA-617, a radiolabeled prostate specific membrane antigen (PSMA) binding dipeptide in Phase 3 for metastatic castration-resistant prostate cancer (mCRPC)

Source: Lutathera USPI; clinicaltrials.gov accessed Sept 2019; https://snmmi.files.cms-plus.com accessed Jan 2020

20

• HCPs in Germany may use experimental agents to treat patients with life-threatening diseases if no other appropriate options available

– Treating physician operates independently – not a formal clinical trial

• Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 from named-patient use at the ICPO Foundation Symposium in December 2019

– Imaged 10 patients with advanced solid tumors including breast, pancreatic, colorectal and ovarian cancers with PET/CT with Gallium-68 FAP-2286

– Images consistent with standard of care 18F FDG-PET/CT scans in the same patients

– Treated 10 patients with Lutetium-177 FAP-2286

– Encouraging tumor accumulation and retention

– Reported lack of significant adverse effects within the first two months after single dose

Initial Clinical Experience Reported from FAP-2286 Named-Patient Use

ICPO = International Centers for Precision Oncology

21

Clovis Oncology Development Program for FAP-2286

• IND enabling studies ongoing; planning to submit IND in 2H 2020

• Phase 1 study to determine the dose and tolerability of the FAP-targeting therapeutic and imaging agent

• Expansion cohorts planned in multiple solid tumor types as part of a global clinical development program

• Potential for accelerated approvals in multiple tumor types

• Opportunity to be a leader in an important new area of oncology development

22

Summary• Estimated $38.3-39.3M in Rubraca® (rucaparib) global ovarian sales for Q4 2019 and $142.0-143.0M for

FY2019

• EU ovarian launches underway in Germany, England and Italy; additional EU ovarian launches anticipated in Q1 2020

• sNDA for Rubraca in BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer filed in mid-November 2019

• Potential U.S. prostate cancer launch in mid-2020

• Multiple studies underway of combinations of Bristol-Myers Squibb’s Opdivo® (nivolumab) with both Rubraca and lucitanib

• Initial data from lucitanib combination studies anticipated at medical meetings in 2020

• Recently acquired rights to FAP-2286, a radiopharmaceutical therapy targeting FAP; Clovis currently planning to file IND in 2H 2020

– Initial clinical experience reported based on named-patient use are encouraging

– Potential to be a leader in an emerging area of oncology development

• Reduced outstanding convertible debt by $123.4M in early January 2020sNDA = Supplemental New Drug Application